Controlled release formulations of riluzole and their uses

A pharmaceutical composition comprising from about 75 mg up to about 300 mg of a compound selected from the group consisting of:

• riluzole;
• N-methyl-2-(methylamino)-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)acetamide;
• 2-(ethylamino)-N-methyl-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)amino)ethyl)acetamide;
• 2-(isopropylamino)-N-methyl-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thia-zol-2-yl)amino)ethyl)acetamide;
• 2-(tert-butylamino)-N-methyl-N-(2-oxo-2-((6-(trifluoromethoxy)benzo[d]thi-azol-2-yl)amino)ethyl)acetamide;
• or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition provides a Cmax at steady state of less than about 0.3 mcg/mL for at least about 24 hours.